Empasiprubart + IVIG (Intravenous Immunoglobulin)
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Multifocal Motor Neuropathy (MMN)
Conditions
Multifocal Motor Neuropathy (MMN), MMN
Trial Timeline
Dec 18, 2024 → Dec 1, 2029
NCT ID
NCT06742190About Empasiprubart + IVIG (Intravenous Immunoglobulin)
Empasiprubart + IVIG (Intravenous Immunoglobulin) is a phase 3 stage product being developed by Argenx for Multifocal Motor Neuropathy (MMN). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06742190. Target conditions include Multifocal Motor Neuropathy (MMN), MMN.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06742190 | Phase 3 | Recruiting |
Competing Products
7 competing products in Multifocal Motor Neuropathy (MMN)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfuvirtide + Tenofovir-Emtricitabine | Roche | Phase 2 | 52 |
| Vivaglobin | CSL | Phase 2 | 51 |
| ARGX-117 | Argenx | Phase 2 | 49 |
| ARGX-117 | Argenx | Phase 2 | 49 |
| mefloquine | Biogen | Phase 1/2 | 38 |
| Tysabri | Biogen | Pre-clinical | 20 |
| HyQvia + Subcuvia | Baxter | Phase 2 | 49 |